MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively ...
An alliance of scientists at the Broad Institute and Bayer Pharmaceuticals have developed a drug candidate, sevabertinib, ...
In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...
Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...
Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their ...
NovoCure advances in cancer care with device-based therapy, key trial catalysts, and strong financials supporting long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback